Trial reportPsychopharmacology2011
Cognitive enhancement following acute losartan in normotensive young adults.
Trial report in Psychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 33 citations in OpenAlex.
- Angiotensin blockade enhances motivational reward learning via enhancing striatal prediction error signaling and frontostriatal communication.Molecular psychiatry · 2023Trial
- The Angiotensin Antagonist Losartan Modulates Social Reward Motivation and Punishment Sensitivity via Modulating Midbrain-Striato-Frontal Circuits.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Trial
- Acute effects of ATNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Article
- The central renin-angiotensin system: A genetic pathway, functional decoding, and selective target engagement characterization in humans.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia.British journal of pharmacology · 2019Review
- Effects of Acute Aerobic Exercise on Cognition and Constructs of Decision-Making in Adults With and Without Hypertension.Frontiers in aging neuroscience · 2019Article
- Angiotensin II Type 1 Receptor Blockers Inhibit KAT II Activity in the Brain-Its Possible Clinical Applications.Neurotoxicity research · 2017Article
- Pleiotropic effects of the acute and chronic inhibition of the renin-angiotensin system in hypertensives.Journal of human hypertension · 2014Observational
- Evidence for a detrimental relationship between hypertension history, prospective memory, and prefrontal cortex white matter in cognitively normal older adults.Cognitive, affective & behavioral neuroscience · 2013Article
- Probable Nootropicinduced Psychiatric Adverse Effects: A Series of Four Cases.Innovations in clinical neuroscienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleLosartan, an angiotensin II receptor antagonist (AIIA), is an antihypertensive that has previously been suggested to have cognitive-enhancing potential for older adults. The objective indices for such effects are equivocal, however, and if these drugs do offer dual advantages of hypertension control plus cognitive-enhancing potential, there exists a clear need to establish this directly.
objectivesThis work examines the potential of losartan administered as a single dose to healthy young adults to improve cognitive performance alone or to reverse scopolamine-induced cognitive decrements.
methodsIn two placebo-controlled, double-blind studies, participants completed a cognitive test battery once before and once after drug absorption. In experiment 1, participants were randomly allocated to receive placebo, losartan 50 mg or losartan 100 mg. In experiment 2, participants were randomly allocated to one of four treatment groups: placebo/placebo, placebo/scopolamine, losartan/scopolamine and losartan/placebo (50 mg losartan p.o. and 1.2 mg scopolamine hydrochloride p.o.).
resultsLosartan 50 mg improved performance on a task of prospective memory when administered alone and reversed the detrimental effects of scopolamine both in a standard lexical decision paradigm (p < 0.01) and when the task incorporated a prospective memory component (p < 0.008).
conclusionsThe findings highlight a cognitive-enhancing potential for losartan on compromised cognitive systems and emphasise the potential of AIIAs to produce benefits over and above hypertension control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.